Desjardins Global Asset Management Inc. Decreases Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Desjardins Global Asset Management Inc. reduced its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 64.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 187 shares of the medical research company’s stock after selling 344 shares during the quarter. Desjardins Global Asset Management Inc.’s holdings in IQVIA were worth $43,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. AdvisorNet Financial Inc boosted its stake in shares of IQVIA by 327.6% in the fourth quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 95 shares during the period. BKM Wealth Management LLC purchased a new position in shares of IQVIA in the fourth quarter valued at $32,000. Activest Wealth Management purchased a new position in shares of IQVIA in the fourth quarter valued at $35,000. Live Oak Investment Partners purchased a new position in shares of IQVIA in the fourth quarter valued at $41,000. Finally, CVA Family Office LLC purchased a new position in shares of IQVIA in the fourth quarter valued at $43,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

IQV has been the subject of several analyst reports. BTIG Research initiated coverage on shares of IQVIA in a research note on Tuesday, February 13th. They issued a “buy” rating and a $285.00 target price for the company. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Friday, February 16th. SVB Leerink started coverage on shares of IQVIA in a research report on Monday, February 26th. They issued an “outperform” rating and a $290.00 price target on the stock. Leerink Partnrs restated an “outperform” rating on shares of IQVIA in a research report on Monday, February 26th. Finally, Barclays raised their price target on shares of IQVIA from $260.00 to $265.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $256.80.

IQVIA Trading Up 0.4 %

Shares of NYSE:IQV opened at $228.09 on Friday. The company has a market cap of $41.40 billion, a PE ratio of 31.29, a P/E/G ratio of 2.20 and a beta of 1.50. The company’s 50-day moving average price is $244.82 and its 200 day moving average price is $221.65. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The company has a quick ratio of 0.86, a current ratio of 0.86 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 EPS for the quarter, topping analysts’ consensus estimates of $2.82 by $0.02. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The company had revenue of $3.87 billion for the quarter, compared to the consensus estimate of $3.80 billion. During the same period in the previous year, the firm earned $2.54 EPS. IQVIA’s revenue was up 3.5% on a year-over-year basis. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.11 earnings per share for the current year.

Insiders Place Their Bets

In other IQVIA news, insider Kevin C. Knightly sold 8,607 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the sale, the insider now directly owns 5,251 shares in the company, valued at approximately $1,313,642.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other IQVIA news, insider Kevin C. Knightly sold 8,607 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the sale, the insider now directly owns 5,251 shares in the company, valued at approximately $1,313,642.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the transaction, the insider now directly owns 796,752 shares in the company, valued at approximately $199,610,278.56. The disclosure for this sale can be found here. In the last three months, insiders have sold 41,285 shares of company stock worth $10,331,003. 1.60% of the stock is owned by corporate insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.